A 2026 mechanistic study involving 28 healthy adults found that a single 25 mg psilocybin session changed acute brain entropy, psychological insight, well-being, cognitive flexibility, and some MRI-derived white-matter signals for up to 1 month. Research Highlights Acute brain entropy rose clearly: 25 mg psilocybin increased Lempel-Ziv complexity (LZc; a measure of signal irregularity) at …
A 2026 study involving 32 adult mangrove rivulus fish pairs found that 3,000 µg/L waterborne psilocybin reduced movement and aggressive swimming bursts, but the result belongs in animal behavioral pharmacology, not in human aggression treatment claims.1 Research Highlights Fish movement decreased: psilocybin produced a treatment-by-time interaction for time spent moving (p = 0.006), with a …
Patients with chronic insomnia frequently end up on both a sleep medication and cognitive behavioral therapy for insomnia (CBT-I), and a 2026 AASM meta-analysis of 15 RCTs from Buysse et al. found a clear asymmetry: adding CBT-I to medication helps, while adding medication to CBT-I adds little and may even worsen daytime depression scores.1 Research …
A 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication signal and most timed cases began within 30 days of drug exposure.1 Research Highlights 28,938 dystonia reports: Chen et al. analyzed 27,618 patients represented in FAERS reports from Q1 2004 through Q3 …
A 2026 target-trial emulation involving 102,361 U.S. veterans with type 2 diabetes found no increased suicidality risk after starting semaglutide vs. sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors): suicidal ideation HR 0.99 and suicide attempt/death HR 1.05 after overlap weighting.1 That does not prove semaglutide prevents suicide, but it weakens the broad claim that semaglutide initiation itself …
A Global Burden of Disease analysis estimated that U.S. age-standardized substance-use disorder disability-adjusted life-year rates rose 213.5% from 1990 to 2019, with opioid use disorders producing the steepest increase and the largest state-level burden.1 Research Highlights U.S. cases rose sharply: prevalent substance-use disorder cases increased from 12.6 million in 1990 to 19.5 million in 2019.1 …
An 11-person case series tested delayed-release apple cider vinegar capsules in young adults who had gained weight while taking psychotropic medications, and metabolic markers carried more signal than weight loss. Research Highlights Feasibility was the strongest result: 11 of 12 enrolled participants completed the study, 10 of 11 completers missed 5 or fewer doses, and …